The mechanically interlocked, AF647–meditope/Ile83Glu anti-HER2 memAb accumulated at the tumor within 24 h of injection and remained at 72 h albeit with less intensity (Fig. 3c, top row). Here, ERBB2 is linked to neoplasm.